Friday, June 5, 2026
ADVT 
National

Study links long COVID and autoimmune disease

Darpan News Desk The Canadian Press, 22 Sep, 2022 10:56 AM
  • Study links long COVID and autoimmune disease

Some long COVID patients suffering symptoms including fatigue and shortness of breath are showing signs of autoimmune diseases like rheumatoid arthritis and lupus, suggests a Canadian study that builds on similar findings elsewhere.

Manali Mukherjee, who led the study and is a respiratory researcher at McMaster University in Hamilton,said two specific abnormal antibodies, or autoantibodies, which attack healthy tissues and are known to cause autoimmune disease, persisted in about 30 per cent of patients a year after they became infected.

The research was based on blood samples from patients who were diagnosed with COVID-19 between August 2020 and September 2021 and received care at two hospitals in Vancouver and another in Hamilton.

The persistence of autoantibodies for a year or longer points to the need for patients to see a specialist who could test for signs of autoimmune disease, she said of conditions that also include Type 1 diabetes and multiple sclerosis.

"If you are having long COVID symptoms, even 12 months after getting COVID, please consider getting a rheumatological checkup, just to make sure that there is no trajectory towards systemic disease," Mukherjee said.

The study, which also involved Dr. Chris Carlsten, from the University of British Columbia's division of respiratory medicine, was published Thursday in the European Respiratory Journal and involved 106 patients.

The work supports emerging research on long COVID, which mostly affects women, Mukherjee said.

A study of 300 patients published earlier this year in the journal Cell by researchers in the United States was the first to show that autoantibodies among those infected with the virus can lead to long COVID symptoms, but it was limited to three to four months after recovery, Mukherjee said.

A Swiss study of 90 patients published last April in the journal Allergy suggested autoantibodies can be present a year following infection in 40 per cent of patients.

"But this study confirms the presence of specific autoantibodies and is further associated with persistence of fatigue and breathlessness, two core long COVID symptoms, at 12 months," she said.

Mukherjee, who contracted long COVID herself in January 2021 after starting her research on the illness, said she experienced fatigue, shortness of breath, headaches and brain fog.

"The headaches used to be so bad, and it relapses. You'll be fine, and then suddenly, you relapse," she said, adding she is back to about 75 per cent of her usual energy level but has learned to prioritize her health over working long hours and ensures she gets enough sleep.

Mukherjee is now studying long COVID patients over two years to see how their levels of autoantibodies change in the longer term.

Calgary resident Sarah Olson said long COVID has prevented her from returning to her job as a kindergarten teacher since she contracted the illness in January 2021.

"There's no such thing as pushing through. You just get sicker and sicker in new ways," said Olson, who has a nine-year-old son and an 11-year-old daughter and deals with brain fog, fatigue, shortness of breath and other symptoms.

"Until this spring, I couldn't stand still for long but I could walk at a moderate pace. Now, I can't do that anymore. I need a walker. I'll be 41 this Saturday, and I need a walker."

Olson said she has also been diagnosed with myalgic encephalomyelitis, or chronic fatigue syndrome, though Mukherjee said a definitive link between that debilitating, long-term condition and long COVID has not been established.

Olson said the main concern is that she will never recover from long COVID.

"If I'm not able to manage my symptoms by resting and pacing as much as I need to without ever getting stressed out, then I have every reason to believe that I would continue to get worse," she said through tears.

"The research needs to hit some breakthrough because they're still trying to understand what the underlying cause is," Olson said, adding that could mean treatment options are far off.

"We're nearly three years in and we're still in the dark in a lot of ways."

MORE National ARTICLES

Ottawa approves made-in-Canada COVID vaccine

Ottawa approves made-in-Canada COVID vaccine
Health Canada says its effectiveness and safety in those under 18 and over 64 have "not yet been established." Clinical trials suggested the vaccine was 71 per cent effective in protecting against COVID-19 one week after the second dose. The dosing schedule is 21 days apart.

Ottawa approves made-in-Canada COVID vaccine

Joly calls Russian envoy on carpet over Ukraine

Joly calls Russian envoy on carpet over Ukraine
The meeting at the Lester B. Pearson Building in Ottawa took place as Prime Minister Justin Trudeau was meeting virtually Thursday with G7 partners to discuss a response. Trudeau said before the meeting that Russia’s actions will be met with severe consequences.

Joly calls Russian envoy on carpet over Ukraine

799 COVID19 cases for Wednesday

799 COVID19 cases for Wednesday
There are 653 individuals hospitalized with COVID-19 in B.C., and 108 are in intensive care.

799 COVID19 cases for Wednesday

Emergencies Act no longer needed: Trudeau

Emergencies Act no longer needed: Trudeau
Trudeau invoked the Emergencies Act, which replaced the War Measures Act in 1988, for the first time last week, saying police needed extra help to end protests against COVID-19 restrictions that had occupied downtown Ottawa for weeks and spread to key Canada-U.S. border crossings.

Emergencies Act no longer needed: Trudeau

Feds commit $140M to keep temporary veterans staff

Feds commit $140M to keep temporary veterans staff
Today’s funding announcement comes after The Canadian Press reported earlier this month that the government was poised to lose hundreds of temporary staff next month.

Feds commit $140M to keep temporary veterans staff

Canada signs agreement with AZ on COVID treatment

Canada signs agreement with AZ on COVID treatment
A release from Public Services and Procurement Canada says the antibody therapy, called Evusheld, is a pre-exposure preventative for COVID-19.    

Canada signs agreement with AZ on COVID treatment